ArticleUrolithiasis2025
Associations of obesity, sarcopenia, and sarcopenic obesity with the risk of kidney stones in the U.S. Adult: results from NHANES 2011-2018.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predicting SIRS after PCNL using machine learning: the joint impact of sarcopenia and staghorn stones.World journal of urology · 2026Article
- Association between sarcopenic obesity and kidney stones: evidence from a prospective cohort study on the UK Biobank.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney stones (KS), a globally prevalent urological disorder, are linked to metabolic abnormalities and inflammation. Sarcopenia, characterized by progressive skeletal muscle loss and functional decline, frequently coexists with metabolic dysregulation. Sarcopenic obesity (SO), defined by reduced muscle mass and/or function combined with excessive adiposity, may synergistically exacerbate health risks beyond isolated sarcopenia or obesity. However, current studies investigating the relationship between obesity, sarcopenia, SO and KS are limited to single-factor analyses, with limited exploration of inflammatory mediation. This study aims to examine the associations of obesity, sarcopenia, and SO with KS, and for the first time, evaluate the mediating effects of inflammatory biomarkers within these relationships. A total of 10, 043 participants aged ≥ 20 years from the National Health and Nutrition Examination Survey (NHANES) were included. Obesity was defined by body mass index and sarcopenia was assessed using the appendicular muscle index (AMI). SO was defined as the coexistence of sarcopenia and obesity. KS was identified through responses to the "Kidney Conditions-Urology" questionnaire. Weighted multivariable-adjusted logistic regression was used to evaluate the correlation between obesity, sarcopenia, SO and the risk of KS. Mediation models were constructed to assess the mediating role of inflammatory biomarkers. In the U.S. adult population, the prevalence of obesity, sarcopenia, and SO were 35.68%, 7.19%, and 5.27%, respectively. Among the population included in this study, the incidence rates of KS among individuals with obesity, sarcopenia, and SO were 9.77%, 10.92%, and 11.95%, respectively. Multiple regression analysis demonstrated significant independent positive associations between all three body composition disorders and KS incidence after comprehensive adjustment for potential confounding variables. Mediation analyses revealed that neutrophil mediated 11.38% (P = 0.0100), 13.60% (P = 0.0200), and 15.55% (P = 0.0120) of the potential effects of obesity, sarcopenia, and SO on KS formation, respectively. Obesity, sarcopenia, and SO were all positively associated with KS risk in U.S. adults. Neutrophil plays a critical mediating role in the relationship between obesity, sarcopenia, SO and KS.
Indexed as
Identifiers
40498351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.